

Nigel P Murray

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1511516/nigel-p-murray-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

253
citations

8
h-index

11
g-index

62
ext. papers

295
ext. citations

2
avg, IF

3.36
L-index

#	Paper	IF	Citations
59	Atypical presentation of COVID-19: Chronic bilateral testicular pain with lower extremity peripheral polyneuropathy, case report. <i>Urology Case Reports</i> , 2022 , 40, 101932	0.5	
58	Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorin and Oxaliplatin based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022 , 23, 591-599	1.7	1
57	Pregnancy in a 31-year-old woman with chronic lymphocytic leukemia: a case report and review of the literature. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 368-370	1.6	1
56	The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone. <i>Colorectal Disease</i> , 2021 , 23, 805-813	2.1	3
55	Management of mild congenital deficiency of Factor XI with a Factor XI inhibitor in pregnancy: A clinical case. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 ,	1.6	
54	Renal infarction associated with asymptomatic Covid-19 infection. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 353-356	1.6	2
53	Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021 , 22, 2391-2397	1.7	1
52	Transient acquired factor XII deficiency associated with moderately severe Covid-19 pneumonia. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 515-517	1.6	2
51	Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome. <i>Colorectal Disease</i> , 2021 , 23, 2879-2893	2.1	1
50	The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. <i>Turkish Journal of Urology</i> , 2020 , 46, 360-366	1.3	
49	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecancermedicalscience</i> , 2020 , 14, 1119	2.7	2
48	The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. <i>Turkish Journal of Urology</i> , 2020 , 46, 360-366	1.3	1
47	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecancermedicalscience</i> , 2020 , 14, 1119	2.7	2
46	The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy. <i>Ecancermedicalscience</i> , 2020 , 14, 1042	2.7	1
45	Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy. <i>Turkish Journal of Urology</i> , 2020 , 46, 115-122	1.3	7
44	The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer. <i>Turkish Journal of Urology</i> , 2020 , 46, 186-195	1.3	
43	The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy. <i>Ecancermedicalscience</i> , 2020 , 14, 1063	2.7	

42	Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy. <i>Hematology, Transfusion and Cell Therapy</i> , 2020 , 42, 283-286	1.6	2
41	Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study. <i>Urology Journal</i> , 2020 , 17, 262-270	0.9	2
40	Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019 , 20, 3385-3389	1.7	7
39	Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. <i>Ecancermedalscience</i> , 2019 , 13, 934	2.7	5
38	Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse. <i>Ecancermedalscience</i> , 2019 , 13, 935	2.7	7
37	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 740-741	2.5	
36	Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 229-236	1.7	11
35	10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 1577-1583	1.7	4
34	Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 3375-3381	1.7	3
33	Transitory Spontaneous Remission of Myelodysplasia in an Elderly Man while Receiving Intravesical Bacillus Calmette-Guérin for Bladder Cancer: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2018 , 2018, 9750532	0.7	
32	Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review. <i>Case Reports in Hematology</i> , 2018 , 2018, 2615838	0.7	2
31	The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy. <i>Ecancermedalscience</i> , 2018 , 12, 844	2.7	1
30	Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management. <i>Biological Research</i> , 2018 , 51, 32	7.6	5
29	The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance. <i>Ecancermedalscience</i> , 2017 , 11, 711	2.7	6
28	CD19 CD56 myeloma arising in a patient who failed two courses of immunosuppressive therapy for aplastic anaemia. <i>Ecancermedalscience</i> , 2017 , 11, 720	2.7	
27	How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome. <i>Turkish Journal of Urology</i> , 2017 , 43, 456-461	1.3	2
26	Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer. <i>Ecancermedalscience</i> , 2016 , 10, 671	2.7	1
25	Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells. <i>BJU International</i> , 2016 , 118, 556-62	5.6	11

24	Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 430.e17-25	2.8	6
23	Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 2941-6	1.7	3
22	Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Aggressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 3089-93	1.7	2
21	Efficacy of Using Sequential Primary Circulating Prostate Cell Detection for Initial Prostate Biopsy in Men Suspected of Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 3385-90	1.7	3
20	Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 203.e19-25	2.8	2
19	Secondary Circulating Tumor Cells (CTCs) but not Primary CTCs are Associated with the Clinico-Pathological Parameters in Chilean Patients With Colo-Rectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 4745-9	1.7	7
18	Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 6615-9	1.7	8
17	Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 7123-7	1.7	3
16	Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 8387-90	1.7	3
15	Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: the BEST (Breast Early Screening Test) study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 1929-34	1.7	9
14	Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 601-6	1.7	1
13	Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 5245-70	1.7	1
12	Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer. <i>Journal of Oncology</i> , 2014 , 2014, 612674	4.5	8
11	A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. <i>BioMed Research International</i> , 2014 , 2014, 676572	3	10
10	Management of Pregnancy in a Chilean Patient with Congenital Deficiency of Factor VII and Glanzmann's Thrombasthenia Variant. <i>Case Reports in Obstetrics and Gynecology</i> , 2014 , 2014, 628386	0.8	2
9	Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 9335-9	1.7	5
8	Acquired melanonychia in Chilean patients with essential thrombocythemia treated with hydroxyurea: a report of 7 clinical cases and review of the literature. <i>ISRN Dermatology</i> , 2013 , 2013, 325246		3
7	Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. <i>Scientific World Journal, The</i> , 2013 , 2013, 762064 ^{2.2}		19

6	Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. <i>Journal of Oncology</i> , 2013 , 2013, 165014	4.5	18
5	Cost-Benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2013 , 66, 277-86	0.4	1
4	Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study. <i>Bone Marrow Research</i> , 2012 , 2012, 259351		15
3	Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol. <i>Indian Journal of Urology</i> , 2011 , 27, 200-7	0.8	10
2	Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy. <i>Archivos Espanoles De Urologia</i> , 2011 , 64, 961-71	0.4	8
1	P504S expressing circulating prostate cells as a marker for prostate cancer. <i>Oncology Reports</i> , 2010 , 24, 687-92	3.5	8